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Abstract
Background: Drug-induced liver injury (DILI) is a major safety concern characterized by a complex and diverse
pathogenesis. In order to identify DILI early in drug development, a better understanding of the injury and models
with better predictivity are urgently needed. One approach in this regard are in silico models which aim at
predicting the risk of DILI based on the compound structure. However, these models do not yet show sufficient
predictive performance or interpretability to be useful for decision making by themselves, the former partially
stemming from the underlying problem of labeling the in vivo DILI risk of compounds in a meaningful way for
generating machine learning models.
Results: As part of the Critical Assessment of Massive Data Analysis (CAMDA) “CMap Drug Safety Challenge” 2019
(http://camda2019.bioinf.jku.at), chemical structure-based models were generated using the binarized DILIrank
annotations. Support Vector Machine (SVM) and Random Forest (RF) classifiers showed comparable performance to
previously published models with a mean balanced accuracy over models generated using 5-fold LOCO-CV inside a
10-fold training scheme of 0.759 ± 0.027 when predicting an external test set. In the models which used predicted
protein targets as compound descriptors, we identified the most information-rich proteins which agreed with the
mechanisms of action and toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs), one of the most important
drug classes causing DILI, stress response via TP53 and biotransformation. In addition, we identified multiple
proteins involved in xenobiotic metabolism which could be novel DILI-related off-targets, such as CLK1 and DYRK2.
Moreover, we derived potential structural alerts for DILI with high precision, including furan and hydrazine
derivatives; however, all derived alerts were present in approved drugs and were over specific indicating the need
to consider quantitative variables such as dose.
Conclusion: Using chemical structure-based descriptors such as structural fingerprints and predicted protein
targets, DILI prediction models were built with a predictive performance comparable to previous literature. In
addition, we derived insights on proteins and pathways statistically (and potentially causally) linked to DILI from
these models and inferred new structural alerts related to this adverse endpoint.
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Background
Drug-induced liver injury (DILI) is a major safety con-
cern and one of the leading causes of drug failure in
clinical drug development and market withdrawal, which
can be found across nearly all classes of medication [1].
DILI may occur either as hepatitis or cholestatic injury
or a mixed form of both and can be further distin-
guished between intrinsic and idiosyncratic DILI [1]. If a
drug is hepatotoxic in a dose-dependent manner both in
preclinical models and humans (e.g. acetaminophen) it is
considered to cause intrinsic DILI. Idiosyncratic DILI,
on the other hand, is characterized by the lack of a clear
dose-dependency and its rarity (usually less than 1 of 10,
000 treated patients develops DILI symptoms). In con-
trast to intrinsic DILI, idiosyncratic DILI is the result of
a patient’s rare combination of genetic and non-genetic
risk factors, which is responsible for their susceptibility
towards the drug [2]. Consequently, in most cases, idio-
syncratic DILI cannot be detected in preclinical studies
[3]. The idiosyncratic nature of DILI also impedes its
prediction with quantitative structure-activity relation-
ship (QSAR) models, as idiosyncrasy implies that the
underlying cause lies beyond inherent compound prop-
erties. Due to the low incidence of DILI, revealing causal
links between the use of a drug and an observed liver in-
jury is a difficult task [4], which decreases the confidence
in provided DILI labels and further complicates the
building of QSAR models with high predictivity.
The limited capability of animal models to detect hep-
atotoxic compounds raises the need for alternative test-
ing strategies including in vitro and in silico models, as
well as a better understanding of the underlying biology.
Major challenges associated with the prediction of DILI
using in vitro approaches lie in identifying relevant as-
says [5] and extrapolating from assay concentrations to
in vivo blood concentrations associated with a hepato-
toxic risk [6]. Numerous in silico models have been gen-
erated based on molecular structure [7–13] and in vitro
readouts, such as bioactivity [14], gene expression [15]
in cell culture or combinations of readouts [16], which
are able to predict DILI better than random, but with a
performance not yet sufficient for decision making in
practice.
In the case of computational predictions, DILI is often
simplified to a classification problem, i.e. separating
compounds with or without this annotation in a data set
[7–9, 11, 14]. These labels, however, do not provide in-
formation on important factors such as dose-
dependency or affected patient population, and conse-
quently, the practical applicability of such models is lim-
ited. While more detailed information on quantitative
compound toxicity is difficult to retrieve, the weight of
evidence for DILI is often provided in the available data-
sets. Paying attention to the quality of the data used for
model generation has previously been shown to be rele-
vant; for example, Kotsampasakou et al. (2017) [9] dem-
onstrated that better models can be derived with
smaller, but higher quality datasets.
The present work is derived from participation in the
Critical Assessment of Massive Data Analysis (CAMDA)
“CMap Drug Safety Challenge” 2019 (http://camda2019.
bioinf.jku.at) where the aim was to develop more pre-
dictive models for DILI from different descriptor spaces.
In this study, we retrieved compound hepatotoxicity an-
notations from the DILIrank [17] and SIDER [18] data-
bases which were used as labels to generate compound-
based DILI classifiers. The annotations in DILIrank were
assigned by considering DILI-related market withdrawals
and warnings in drug labels in combination with asses-
sing causal links between the use of the drug and the oc-
currence of DILI. The drug is annotated as “DILI
positive” in two different severity classes (“vMost-DILI
concern” and “vLess-DILI concern”) only if casual links
to DILI could be confirmed. Drugs with existing concern
but lack of causal proof were annotated as “Ambiguous
DILI concern”, whereas drugs without concern were an-
notated as “vNo-DILI Concern”. The task set by the
CAMDA challenge was to predict the labels of 55 drugs,
which were previously annotated as “Ambiguous DILI
concern” and recently re-classified by the FDA. To this
end, multiple descriptors were derived from chemical
structure which were used to build classification models
for DILI: chemical fingerprints [19] describing the 2D
compound structure, as well as Mordred molecular de-
scriptors [20], and predicted protein targets inferred with
PIDGIN [21–23]. The predictivity of the resulting
models was evaluated using two different external test
sets. Models were also built using the L1000 gene ex-
pression data provided by CAMDA, but these did not
perform significantly better than random and were not
analysed further (Additional file 1).
In addition to predictive performance, we also fo-
cused on two practically relevant aspects of DILI pre-
diction, namely the ability of models to extrapolate in
chemical space, as well as the interpretation of relevant
molecular and biological factors underlying DILI since
interpretable models are more trusted, for example by
regulatory agencies [24]. To gain insights into biological
processes, the protein targets with significantly higher
binding probability in DILI compounds and the highest
information for DILI classification were extracted from
the protein target-based machine learning models.
Based on these, we identified biological processes asso-
ciated with DILI labels in the current dataset using gen-
esets derived from MSigDB [25] to show that
mechanistic understanding of the biology underlying
DILI can be obtained from this chemical structure-
based feature space.
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From the purely chemical side, we derived interpret-
able structural alerts related to DILI with the Molecular
Substructure miner algorithm (MoSS) implementation
of graph-based Molecular Fragment miner algorithm
(MoFa) [26] and the fragment-based SARpy package
[27], which could guide lead optimization to reduce the
risk of DILI, as is currently standard practice for other
toxicities [28]. We then compared the quality of the de-
rived structural alerts against the recent review of DILI
related structural alerts by Liu et al. (2015) [29].
Results
Predictive modeling
We first compared the performance of Support Vector
Machine (SVM) and Random Forest (RF) models trained
using different input descriptors to predict DILI positive
compounds. To this end, three datasets with differing
levels of DILI label confidence and size were compared
(summarized in Table 1): “DILIrank (−vLessConcern)”,
comprising DILIrank compounds labelled as either
vMostConcern or vNoConcern (high confidence),
“DILIrank” which additionally contains compounds from
the DILIrank vLessConcern class (low confidence), and
“DILIrank (+SIDER)” which additionally includes inac-
tives from the SIDER database (low confidence).
It can be seen in Fig. 1 that models trained using Ex-
tended Connectivity Fingerprints of diameter 4 (ECFP4)
descriptors show similar predictive performance for both
the Leave-One-Cluster-Out cross-validation (LOCO-
CV) and the external test set across all datasets for both
the RF and SVM algorithms. For example, RF models
trained using the DILIrank (−vLessConcern) dataset had
a mean balanced accuracy of 0.734 ± 0.044 during cross-
validation and 0.746 ± 0.032 for the external test set
(Table S1). Secondly, all models achieved higher predic-
tion accuracy than y-scrambling models (Fig. 1), demon-
strating they all had a predictive power exceeding that of
pure chance [30]. Thirdly, for LOCO-CV and external
test set a slightly better predictive performance was
found using the highest confidence dataset in compari-
son to the lower confidence datasets, although it should
be noted that these models are not directly comparable
given the varying dataset sizes (Fig. 1 and Table 1). For
example, for the SVM models the LOCO-CV mean bal-
anced accuracy decreased from 0.714 ± 0.058 on the
DILIrank (−vLessConcern) to 0.671 ± 0.043 (DILIrank)
and 0.643 ± 0.045 (DILIrank (+SIDER)). Moreover, the
mean external test set balanced accuracy decreased from
0.759 ± 0.027 (DILIrank (−vLessConcern)) to 0.697 ±
0.048 (DILIrank) and 0.709 ± 0.036 (DILIrank (+SIDER)).
These three findings were also observed for models
trained using Mordred molecular descriptors [20] and
protein target descriptors [21, 22] (see Table S1, and
Figs. S1 and S2).
A significant drop in performance is seen for the ma-
jority of models on the FDA validation set with a bal-
anced accuracy of below 0.6 (Fig. 1), which indicated
that the models were less capable of generalizing to the
FDA validation set than to the external test set. These
findings were also observed for models trained using
Mordred molecular descriptors [20] and protein target
descriptors [21, 22] indicating the limited generalization
of models occurred irrespective of descriptor space. The
best performing model across the most metrics was the
SVM model trained using the DILIrank (−vLessConcern)
dataset which utilized a linear kernel, a C parameter of
0.1, and a ‘one vs. rest’ decision function. This model
achieved a mean balanced accuracy of 0.759 ± 0.03 and
0.655 ± 0.00 on the external test set and FDA validation
set, respectively, thus demonstrating relatively high pre-
dictive power across the two independent test sets com-
pared to all other models generated (Fig. 1 and Table
S1).
We next investigated the relationship between a com-
pounds’ Tanimoto similarity to its 5 nearest neighbors
in the training set and its classification performance for
the external test set (Fig. 2a). This was achieved by gen-
erating a SVM model (with the same hyperparameters as
the best model noted previously) where within each fold
of a Leave-One-Out cross-validation (LOO-CV) scheme
a compound’s predicted DILI label and Tanimoto simi-
larity to the training set were retrieved (see Methods).
Note that such an analysis for the FDA validation set
was not possible as the DILIrank labels for this set of
compounds were withheld. It was found that 65% of the
compounds with a mean Tanimoto similarity to their 5
nearest neighbors in the training set between 0.0–0.2
were correctly classified (already comparable to the pre-
dictive performance on the FDA validation set for the
same model - mean accuracy 0.673 ± 0.000), and this in-
creased to 89% for compounds with 0.4–0.5 Tanimoto
Similarity, and subsequently to 100% for compounds
Table 1 Datasets used to generate predictive DILI models
Dataset Name Data samples Binary class
vLessConcern (n = 260) vMostConcern (n = 174) vNoConcern (n = 227) SIDER (n = 262) n (DILI) n (NoDILI)
DILIrank (−vLessConcern) – DILI NoDILI – 174 227
DILIrank DILI DILI NoDILI – 434 227
DILIrank (+SIDER) DILI DILI NoDILI NoDILI 434 489
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Fig. 1 DILI label prediction performance (balanced accuracy) of RF and SVM models trained using ECFP4 descriptors. Models were trained using
the datasets described in Table 1. Performance is stable between the 5-fold LOCO-CV and external test set, but a distinct drop in predictive
accuracy is observed when predicting the FDA validation set. Hence, despite demonstrating a capability to generalize to new compounds (not
seen during training) in the external test set, models lacked the capability to generalize to the new compounds in the FDA validation set
Fig. 2 Analysis of the link between chemical similarity and classification performance. a Classification rate during LOO-CV vs. mean 5 NN
Tanimoto compound similarity. A clear link between correct classification rate (%) and chemical similarity is observed in the DILIrank
(−vLessConcern) dataset. The only exception from this was the first bin, which was defined by only a single compound (n = number of correctly
classified compounds) and hence not a representative rate), and indicated that external test set compounds that are more structurally similar to
the training set were predicted better. b Distribution of the mean 5 nearest neighbour inter-similarities between the DILIrank (−vLessConcern)
training dataset and the corresponding test sets. It was found that the 55 FDA validation set compounds had comparable structural similarity to
the training set (orange) as the compounds within the external test set (blue). Both histograms are left-closed
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with a Tanimoto similarity greater than 0.5 (Fig. 2a). As
similar inter-similarity distributions were found between
the training dataset and both the external test and FDA
validation sets (Fig. 2b), one could have naively antici-
pated a higher predictive performance (in line with the
external test set) for the FDA validation compounds
than seen in practice (Fig. 1).
Biological interpretation of protein targets
We next compared the median feature importance of
proteins in the RF and SVM model based on the DILIr-
ank (−vLessConcern) dataset which showed the best
classification performance with protein target descrip-
tors across LOCO-CV, external test set and FDA valid-
ation set (Fig. S2). The Pearson correlation between the
models' absolute respective feature importance is low
(0.29) indicating that overall they identify different pro-
tein targets as being important for DILI classifica-
tion. (Fig. 3)
Given that the focus is set on proteins with bioactivity
related to DILI risk, we only further examined those that
were significantly enriched in DILI-related compounds
as determined by a Wilcoxon rank test. This included al-
dose reductase AKR1B1 which has been linked to
APAP-induced oxidative stress and hepatotoxicity [31],
the CYP enzymes CYP1A2 and CYP2C9 which are in-
volved in xenobiotic metabolism in the liver [32], and
the p38 kinase MAPK11 which is known to mediate
stress-related signals in hepatotoxicity [33]. Moreover,
aldo-keto reductase family 1 member C3 (AKR1C3) is
essential for Phase II drug metabolism pathways and
Transmembrane prolyl 4-hydroxylase (P4HTM) inacti-
vation has reported to have a protective role against
DILI [34–36].
However, novel proteins were also identified such as
Dual specificity protein kinase (CLK1) and dual-
specificity tyrosine-phosphorylation related kinase 2
(DYRK2). Interestingly, one of the identified novel pro-
teins, namely Adenosine A1 Receptor (ADORA1), is a
Fig. 3 Distribution of protein feature importance in the best performing RF and SVM models. Proteins significantly enriched in the DILI class are
labelled in orange, while all other proteins are colored in blue. Among the proteins with high feature importance are many whose involvement in DILI
has been established before, such as AKR1B1, CYP1A2 and MAPK11, and this analysis might give further hints at novel proteins involved in DILI
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member of the same protein family as ADORA2A,
which is known in liver damage [37, 38]. In fact, the ad-
enosine receptors ADORA1 and ADORA2 share physio-
logic functions [39, 40] and ADORA1 has been found to
contribute to renal dysfunction associated with acute
liver injury in rats, supporting a plausible involvement of
this target in DILI [41]. A full list of the proteins identi-
fied as containing the highest feature importance for
classification of the current dataset with the RF and
SVM methods and their known or potential links to
hepatotoxicity are shown in Table S2.
In a next step, over-represented pathways were deter-
mined among the top protein targets, which were signifi-
cantly enriched in the DILI positive compounds (false
discovery rate (FDR) < 0.05) and showed high feature im-
portance in either the RF or SVM models. While results
across different feature importance thresholds are shown
in Figs. S3 and S4, representative results of this analysis
based on the 19 targets with the highest feature import-
ance, respectively, are shown in Fig. 4. From both the RF
and SVM models, biotransformation and Cytochrome
P450 were identified as significantly overrepresented
processes, each based on multiple genesets (see Table
S3, Fig. S3 and Fig. S4), and the involvement of these
two pathways in liver damage has been extensively char-
acterized, especially for injuries related to drug metabo-
lites [42–46]. Moreover, arachidonic acid metabolism
and metabolism of lipids were retrieved by the SVM
models, which play a well-established role in DILI, espe-
cially for injuries induced by acetaminophen [47, 48]. In
contrast, RF identifies p53 signaling and prostaglandin
synthesis as characteristic for DILI from the data (Fig.
4), which are key regulators of cellular stress response
with a specific protective role against liver damages [49,
50]. Of note, prostaglandin synthesis and arachidonic
metabolism are strictly related processes and have been
identified by both RF and SVM at different feature im-
portance thresholds (Fig. S3 and Fig. S4). In fact, prosta-
glandins are metabolites of arachidonic acid, whose
production is controlled by cyclooxygenase (COX),
which, in turn, is inhibited by NSAIDs, involved in DILI
as stated above [51, 52]. Progesterone-mediated oocyte
maturation is also over-represented in SVM and proges-
terone itself has a protective role against DILI [53]. More
specifically, the proteins in this geneset point to cell
cycle (M-phase inducer phosphatase 1 CDC25A, as well
as the cyclins CCNB2 and CCNB3) and cell growth
(RPS6KA6) with a reported role in DILI for Cyclin B2
CCNB2 [54]. Hence, both algorithms prioritize proteins
known to be involved in key processes in DILI. The
same analysis with the lower-performing models based
on the DILIrank and DILIrank (+SIDER) datasets did
not retrieve as many relevant proteins and pathways (re-
sults not shown).
Structural alerts
Two hundred thirty-three MoSS structural alerts (SAs)
and 20 SARpy SAs were derived from the DILIrank
(−vLessConcern) dataset, of which 23 and 11 were
deemed significant (p-value ≤0.05), respectively. The
Fig. 4 DILI-related processes inferred from predicted targets and pathway annotations. Processes were based on SVM (red) and RF (yellow)
models or both (orange) on the DILI (−vLessConcern) dataset. All processes are linked to the corresponding over-represented proteins in grey (19
proteins with highest feature importance). Multiple highly similar genesets were combined to arachidonic acid metabolism, Cytochrome P450
and biotransformation with the individual genesets being mapped in Table S3. Biotransformation and Cytochrome P450 are identified by both
methods, while additional pathways identified by SVM point to lipid metabolism and cell cycle, and TP53 regulation is identified by RF. Moreover,
arachidonic acid metabolism (SVM) and prostaglandin synthesis (RF), two biologically closely related processes, are identified
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number of derived SAs was sensitive to the parameters
chosen and reflects the implementation of both algo-
rithms (Methods). The quality of the inferred SAs,
alongside 12 derived from the recent review literature of
Liu et al. (2015) (5 of them were significant) [29], was
assessed using multiple metrics (Table S4), with a par-
ticular focus on precision and coverage among com-
pounds labelled as DILI positive (Fig. 5), with a
summary of metrics per structural alert source in
Table 2. Furthermore, an analysis of the occurrences of
SAs in DrugBank [55] approved compounds was
conducted.
Overall, for both data- and literature-derived SA a
common trade-off between precision and coverage was
observed i.e. if a substructure had a high precision it
rarely had a high coverage (Fig. 5). For example, the SAs
benzene derivative (SARpy) and aniline derivatives
(SARpy) had relatively low precision (0.47 and 0.65) rela-
tive to the mean precision of 0.85 ± 0.18 for SARpy SAs,
but conversely had relatively high coverage (77.59 and
31.61%) relative to the mean coverage of 14.11 ± 22.54%
for SARpy SAs. Table 2 affords a comparison between
the precision and coverage of SA from each of the three
sources analyzed in this study. In particular, it was noted
that the SAs extracted by Liu et al. [29] had lower cover-
age than those generated by MoSS and SARpy, but that
SAs from all sources had high precision on average. Fur-
thermore, it was seen that SAs from all methods were
found in at least some approved compounds from the
DrugBank database.
A maximum precision of 1 occurred for 29 out of 39
of the significant SA, of which hydrazine derivative was
seen for all three sources and had the highest coverage
in DILI positive compounds (7.47%). Thus, despite the
fact, for example, that SARpy could generate SAs with a
precision of 1, the analyzed SAs were overly specific and




Overall, the most predictive model generated in this
study was an SVM model (linear kernel, C = 0.1, ‘one vs.
rest’ decision function) trained using the DILIrank
(−vLessConcern) dataset, and ECFP4 chemical structure
descriptors. In contrast to non-linear models such as
those generated using RF, the linear kernel utilized by
this SVM model ensured a lack of interaction between
input variables which may have facilitated the model’s
improved generalization properties. This model ranked
third and first for cross-validation (0.714 ± 0.058) and
external test set (0.759 ± 0.03), respectively, by balanced
accuracy, across a compendium of studies that sought to
develop classification models for DILI, despite the sig-
nificantly smaller dataset used for model training in this
study (Table 3). It should be noted that datasets, fea-
tures, and cross-validation schemes used across these
studies vary and therefore performance metrics can
hardly be compared directly. Among others, a LOCO-
CV scheme was implemented in the present study to
avoid predicting compounds with high Tanimoto simi-
larity to the training data, which is more conservative
than the random splits used by Kotsampasakou et al. [9]
Fig. 5 Precision and percentage coverage of significant DILI-related structural alerts (SAs) (p-value ≤0.05). The maximum coverage of SAs was
77.6% (benzene derivative generated by SARpy), however the average coverage was much lower - 6.68%. All MoSS-derived SAs had a precision
of 1, the precision of SARpy SAs was lower on average but still relatively high - mean precision 0.85, and literature-derived alerts had a mean
precision of 0.88
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(Table 3) and translated to a more rigorous evaluation of
internal model performance.
Two key trends relating to training data quality and
model bias were identified. Firstly, a large proportion of
models, irrespective of descriptor type, showed consist-
ent performance between cross-validation and the exter-
nal test set, but then observed a steep drop in
performance on the FDA validation set (Figs. 1, S1, and
S2) despite showing similar chemical similarity distribu-
tion to the training set as seen for the external test set
(Fig. 2b). One explanation for this is that both test sets
populate different regions of chemical space with the
model showing better performance in one area, or that
while populating similar regions of chemical space, these
are not clearly attributed to one of the DILI classes and
intrinsically difficult to predict. An alternative explan-
ation for the lack of generalization could also be attrib-
uted to the fact that compounds in the training data and
external test set were labeled with higher confidence and
hence the model might be able to distinguish between
DILI positive and DILI negative compounds well. In
contrast, the compounds of the FDA validation set, ori-
ginally being labeled as ambiguous due to lack of clear
evidence, might be inherently more difficult to predict.
Deriving accurate DILI labels for compounds is a com-
plex process given the uncertainty of causality assess-
ment and the difficulty in trying to incorporate
administration factors such as dose and patient popula-
tions. Moreover, phenomena such as idiosyncratic DILI
which cannot usually be detected even in preclinical
studies and occur only in subpopulations make the task
of accurate DILI labeling even harder [3].
Secondly, across all descriptor types (ECFP4, Mordred
molecular descriptors, and predicted protein targets) bal-
anced accuracy in the cross-validation and on the exter-
nal test set decreased as the training dataset was
expanded from the high confidence dataset (DILIrank
(−vLessConcern)) to either of the lower confidence data-
sets - DILIrank or DILIrank (+SIDER) (Figs. 1, S1, and
S2). This indicated that the inclusion of compounds
from the vLessConcern class from DILIrank i.e. those
with lower annotated evidence for DILI risk, as well as
inactives derived by text-mining of package label inserts
of marketed drugs (SIDER), harmed predictive perform-
ance despite increasing the number of training samples.
While this is consistent with previous studies [9] which
demonstrated that careful data curation can lead to im-
proved performance, it should be noted that the sample
Table 2 Metrics for DILI-related significant structural alerts (p-value ≤0.05)
Source Mean precision Mean coverage (%) Min. compound presence in DrugBank Max. compound presence in DrugBank
Liu 0.88 ± 0.11 6.09 ± 1.55 25 89
MoSS 1.0 ± 0.0 18.73 ± 10.73 3 41
SARpy 0.85 ± 0.18 14.11 ± 22.54 11 1400
Mean precision and coverage (%) of significant structural alerts from MoSS, SARpy, and Liu et al. (2015) indicated that highly precise SAs alerts were generated
from all three sources, but that these observed varying degrees of coverage. The minimum and maximum presence of SAs for each source in DrugBank approved
compounds demonstrated that all SAs were found in at least some approved compounds, but that the absolute frequency varies significantly between SAs
Table 3 Comparison of performance indicators to several DILI classification models reported in the literature
















10-fold, random splits 0.645 0.680 0.588 0.536 Kotsampasakou





0.767 0.948 0.597 0.848 Zhang et al.
(2016) [10]






0.701 0.799 0.719 0.909 Ai et al. (2018)
[7]
Ensemble of eight different

















0.759 ± 0.03 0.724 ± 0.08 Present study
Literature model performance derived from He et al. (2019) [8]. External test values quoted for the model developed in the present study are for the external test
set. Despite being trained on the fewest compounds (401) and using a conservative LOCO-CV cross-validation scheme, the SVM model developed in the present
study demonstrated robust predictivity between cross-validation and external test set
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size of the external test set and in particular the FDA
validation set (49 compounds) were small. This makes it
difficult to accurately evaluate model performance and
accordingly also to confidently compare models (Fig. 1).
Larger datasets would be required to allow for en-
hanced fine-grained sampling of chemical space and the
establishment of a model applicability domain. In the
present study, the poor generalization to the FDA valid-
ation set demonstrated that the relationship between
chemical structure and the propensity to cause DILI is
too complex for the model to learn from the small train-
ing dataset used (401 compounds). However, it must be
noted that even if larger and higher quality datasets were
acquired, model predictivity would still be limited as
relevant information that may relate to the manifestation
of DILI such as dose or the influence of metabolism in
the formation of hepatotoxic prodrugs were not consid-
ered in the descriptors used in the present study.
Protein targets
From the models which used predicted protein targets
as features, we extracted biological processes by incorp-
orating prior knowledge on bioactivity using PIDGIN
and the functional contexts of proteins based on path-
way maps from multiple databases derived from MSigDB
[25]. SVM and RF both identified biotransformation and
Cytochrome P450, two important pathways involved in
drug metabolism and elimination and strictly related to
DILI [42–46]. Moreover, arachidonic acid metabolism
and prostaglandin synthesis are identified, which are
physiologically involved in the inflammation process [49,
50] and the mechanism of action and toxicity of NSAI
Ds, one of the most common causes for DILI [51, 52].
While the inferred biological processes have been known
to be associated with DILI, this is not true for many of
the proteins identified by feature importance themselves
(Table S2), such as CLK1 and DYRK2. Given that the
analysis was based on target binding probabilities, it can
be hypothesized that these proteins might be off-targets
directly (or indirectly) involved in the pathogenesis of
DILI. The described workflow hence was able to derive
functional hypotheses on biological processes from com-
pound DILI annotations, which can subsequently be in-
vestigated experimentally.
Structural alerts
In this study, structural alerts (SAs) related to DILI were
derived using the SARpy [27] and MoSS [26] algorithms
using the DILIrank (−vLessConcern) dataset. Both MoSS
and SARpy derived SA were found to be comparable to
those reviewed by Liu et al. (2015) [29] in terms of preci-
sion and coverage. It should be noted that in contrast to
the SA of SARpy and MoSS which were explicitly de-
rived and subsequently tested on the dataset used in this
study, the SA of Liu et al. (2015) were derived using data
from different sources, mainly LiverTox [56].
Of the significant SA obtained by SARpy, MoSS, and
Liu et al. (2015) only hydrazine derivative (NN) was
found to overlap between all of them (Table 4) and this
obtained a precision of 1. However, a DrugBank [55]
database search of the significant SA showed that all of
the significant SA derived using MoSS occurred in at
least 3 approved drugs, and those from SARpy and by
Liu et al. (2015) occurred in at least 10 approved drugs
(Table S4). For example, aniline derivative (SARpy) and
carbamide derivative (SARpy), were present in 422 and
80 marketed drugs, respectively (Table S4). From the
methodological angle it illustrated that whilst SA can be
informative about an increased probability of a com-
pound being toxic, the presence of all structural alerts
analyzed in this study in DrugBank approved com-
pounds demonstrated they are not diagnostic of DILI in
isolation. Administration dose is a key consideration to
make when developing therapeutics and is not taken
into account when simply screening for the presence of
a structural alert. For example, hydrazine derivatives
(shared between SARpy, MoSS, and Liu et al. (2015))
can increase muscle, neural, kidney, liver, blood and
spleen toxicity [57], however, it is present in e.g. procar-
bazin, which is a registered antineoplastic agent used in
Hodgkin’s disease treatment and is an orphan drug for
glioma [58]. This example demonstrates that it can be
beneficial to accept an increased toxicity risk in favor of
prolonging the patient’s life.
SAs can play a supportive role in initial screening and
exploratory analysis by flagging potentially toxic com-
pounds early [59, 60] and guiding lead optimization by
medicinal chemists [61]. Their main advantage is that
they are easy to understand and implement [62]. How-
ever, one should be cautious when interpreting fre-
quency analysis results in the case of complex endpoints
as SAs might not capture sufficiently the underlying bio-
logical mechanisms resulting in high false positive and
false negative rates [63].
Conclusions
In this study, DILI classifiers were trained using data
from the DILIrank and SIDER databases, by employ-
ing the SVM and RF algorithms with either ECFP4
fingerprints, Mordred molecular descriptors, or pre-
dicted protein targets as chemical structure-derived
descriptors. The best predictive performance was seen
when using more reliable data (excluding the DILIr-
ank vLessConcern class and SIDER text-mined inac-
tives). This underlines the importance of data quality
for such approaches, although it should be noted that
a true comparison is difficult given the difference in
size between datasets, and the generally small number
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of samples. The best model achieved comparable per-
formance in cross-validation and on the external test
set to models reported in the literature (Table 3). On
the other hand, performance on an additional test set
provided by CAMDA (http://papers.camda.info/) was
much lower, underlining the difficulty of accurately
validating DILI models given the low number of la-
beled compounds. In the present study, the datasets
used to evaluate the DILI model were both small,
consisting of 80 (for the high confidence dataset) and
49 compounds respectively, with the latter proving
much more difficult to predict despite the comparable
structural similarities of the two datasets to the model
training dataset.
Protein target descriptors achieved inferior predictive
performance, but their advantage, compared to Mordred
molecular descriptors and ECFP4 fingerprints, is that
each individual feature corresponds to a protein and is
hence interpretable from a biological perspective. Based
on the feature importances in predictive models, it was
hence possible to identify known and potentially novel
key proteins involved in DILI, as well as important bio-
logical processes in drug-induced liver apoptosis, such as
biotransformation and the mechanism of action and tox-
icity of NSAIDs, which are known to be a common
cause for DILI.
Moreover, we inferred structural alerts with compar-
able precision and coverage to previously derived ones.
However, due to the high structural diversity of DILI an-
notated compounds, the derived alerts were found to
have rather low compound coverage by themselves.
Moreover, all alerts were found to be present in ap-
proved drugs further highlighting the challenge in deriv-
ing practically useful structural alerts for DILI, and
underlining the importance of quantitative factors such
as dose when screening compounds for DILI. Hence,
overall, this work achieved similar results as seen in pre-
vious studies with respect to performance of predicting
DILI; on the other hand it introduced the utilization of
biologically interpretable predicted protein targets to the
field and underlined the importance of large and reliable




Compounds’ SMILES strings were retrieved from the
DILIrank database (1036 compounds) [17], and the
SIDER 4.1 database (1430 compounds) [18]. Side effects
are recorded in SIDER using the preferred terms of the
MedDRA (Medical Dictionary for Regulatory Activities),
which provides a hierarchical organization of adverse
events. Starting with the entire SIDER dataset (SIDER
4.1), all compounds with at least one reported side effect
contained in the MedDRA’s System Organ Class hepato-
biliary disorders were discarded to keep only drugs for
which no liver-related side effects have been reported.
The SMILES retrieved from DILIrank and SIDER were
standardized using the Python package Standardiser of
Atkinson et al. (2016) [64]. This involved the removal of
counterions and solvents and the neutralization of the
remaining fragments if necessary. Moreover, tautomers
were standardized according to the rules implemented
in the standardizer. Subsequently, compounds that fell
into at least one of the following categories were dis-
carded: mixtures of more than one active ingredient, in-
organic molecules, metal-organic compounds, and
compounds with a molecular weight above 1 kDa. If
compounds were present in both the DILIrank and the
SIDER dataset, the compound from the SIDER inactive
dataset was removed to avoid duplicate entries. The final
set contained 923 compounds composed as follows:
DILIrank: 174 vMost-DILI-Concern, 260 vLess-DILI-
Concern, 227 vNo-DILI-Concern, SIDER: 262 com-
pounds without reported liver-related side effects.
ECFP4 [17] hashed to 2048 bits were generated using
the Python library RDKit (version 2019.03.1.0) [65]. One
thousand one hundred eighty-nine 1D and 2D molecular
descriptors were generated using the Python package
Mordred [20]. For the generation of models, the values of
the molecular descriptors were scaled to a Gaussian distri-
bution with zero mean and unit variance using the Stan-
dardScaler function in the scikit-learn Python library
(version 0.21.2) [66]. Bioactivity for 1673 human protein
targets was predicted using the PIDGINv3 software [21–
23]. 10 μM was chosen as the bioactivity cut-off to con-
sider highly and marginally active compounds. To get a
Table 4 DILI-related significant structural alerts (p-value ≤0.05) with the highest precision and coverage (%)



















1 5.75 0,0002 19 diloxanide furoate
The following quality metrics are shown for the best substructures from MoSS, SARpy, and Liu et al. (2015): Precision, coverage in DILI positive compounds (%), p-
value, as well as the number of approved compounds in Drugbank [44] which contain the substructure, alongside an example of such a structure
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prediction for every compound-target pair, no threshold
for the applicability domain was applied. For 6 out of the
923 drugs (4 of them from SIDER) no protein target pre-
diction was made, since their structures could not be stan-
dardized internally in the PIDGINv3 software.
In order to implement a LOCO-CV scheme (to ensure
similar compounds were not in different folds), we per-
formed hierarchical clustering of compounds. Based on
pairwise Tanimoto similarities calculated using ECFP4, a
tree was generated using hierarchical clustering with the
Nearest Point Algorithm implemented in SciPy (version
1.2.1) [67]. Clusters were generated by cutting the hier-
archical tree at a distance of 0.5, which resulted in com-
pounds with a Tanimoto similarity of at least 0.5 being
in the same cluster.
Model generation
Overview
We chose SVM and RF as methods as they have demon-
strated good and robust performance, and are less prone
to overfitting in comparison to more sophisticated
methods. For both methods, we used the scikit-learn Py-
thon library (version 0.21.2) implementations to train
binary classification models for DILI. Models were devel-
oped for all three input feature spaces (ECFP4 finger-
prints, protein targets, and Mordred molecular
descriptors). In addition, we generated models using dif-
ferent subsets of data considering different DILIrank
classes as well as additional inactives from the SIDER
database (Table 1).
Model Hyperparameter grid search
Firstly, for SVMs [68] we used a classifier as implemented
in the sklearn Python library and performed a hyperpara-
meter grid search over the following parameters: Kernel:
[‘linear’], Class weight: [‘balanced’], Decision function:
[‘one vs. rest’], Shrinking: [‘True’], C: [0.05, 0.1, 0.2, 0.3,
0.4, 0.5, 1]. Of the possible SVM kernels implemented
sklearn, we only evaluated ‘linear’ as it alone allows for
easy interpretation of model feature importances. Sec-
ondly, for RFs [69] we used a classifier as implemented in
the sklearn Python library and performed a hyperpara-
meter grid search over the following parameters: Boot-
strap: [‘True’], Class weight: [‘balanced subsample’], Max.
Tree depth: [10, 15, None], Min. samples per leaf: [1–3],
Number estimators: [100, 200, 300, 400, 500, 750, 1000].
Training procedure
The predictive performance of models was evaluated
using a 5-fold cross-validation inside a 10-fold training
scheme. The original dataset was split into 10 stratified
folds based on DILI class label using the StratifiedKFold
function in scikit-learn with parameters: n_splits = 10,
and shuffle = True to assess the impact of different
training data on model predictive performance. Within
each training fold, an internal grid search over model
hyperparameters was conducted using an internal 5-fold
LOCO-CV to select the best model per training fold.
The best model in each fold, assessed by balanced accur-
acy, was then used to predict for the holdout external
test set. The LOCO-CV scheme was implemented with
the GroupKFold function in scikit-learn with clusters
only containing compounds with a ECFP4 Tanimoto
similarity [70] greater than or equal to 0.5. This cross-
validation scheme was utilized irrespective of the de-
scriptor type. In addition, baseline models were trained
and evaluated using the same procedure as mentioned,
but with prior y-scrambling of the output labels (3 runs
of different random scramblings). To further evaluate
model predictive performance, an FDA validation set
composed of 49 compounds (a subset of 55 - the
CAMDA organizers removed 6, of which were unknown
to the authors) previously labeled as vAmbiguous-DILI-
Concern, but later relabeled as DILI positive or DILI
negative by the FDA was used as an additional test set.
To evaluate the relationship between the mean chem-
ical similarity of a compound to its 5 nearest neighbors
in the training set and model correct classification rate a
LOO-CV was conducted for the best performing model
(SVM, DILIrank (−vLessConcern, (Fig. 2a). This re-
quired the calculation of the Tanimoto similarities be-
tween the training dataset and the left-out compound
using ECFP4 fingerprints and predicting its DILI label
within each LOO-CV fold. Furthermore, the Tanimoto 5
nearest neighbor inter-similarity of the FDA validation
set to the training set was compared to the correspond-
ing similarities of the external test set (Fig. 2b). As we
previously evaluated the performance of the model
(SVM, DILIrank (−vLessConcern)) with 10 distinct ex-
ternal test sets (in a 10-fold cross-validation scheme; see
above), the similarities are averaged across all 10 pairs of
training and test set.
Balanced accuracy (eq. 1) was primarily used to assess
the predictive performance of the models. We also uti-
lized specificity to compare models to those previously
published in the literature (Table 3). Those metrics were
calculated from a confusion matrix consisting of true
positives (TP), true negatives (TN), false positives (FP)
and false negatives (FN).
Balanced Accuracy ¼
TP
TP þ FNð Þ
þ
TN
TN þ FPð Þ
2
ð1Þ
Interpretation of protein targets
Protein targets with higher binding probability in DILI
positive compounds, called DILI-enriched targets, were
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determined using a one-sided Wilcoxon rank-sum test
with a FDR of < 0.05. Among those, proteins features
with high median importance across the 10 train-test
splits were identified for RF and SVM models, respect-
ively. The feature importance for RF models imple-
mented in scikit-learn [66] describes the decrease of
node impurity achieved by a feature, averaged over all
trees in the forest, as a fraction, so that the importance
of all features included in the model sum up to 1 [69].
In SVM models using linear kernels the importance of
features is reflected by the magnitude of their coeffi-
cients describing the hyperplane [68]. The sign indicates
which class is favored by the presence of a given feature.
The values used for further analysis were the median im-
portance of a feature across the 10 train-test splits.
Over-enrichment analysis was performed using the
clusterprofiler R package (version 3.17.5) [71]. For this,
pathway maps were derived from MSigDB [25] via the
msigdbr R package from Reactome [72], KEGG [73] and
Wikipathways [74]. To this end, the protein targets with
highest feature importance were mapped to Entrez gene
IDs with the biomaRt package [74] and the list of PIDG
IN target proteins was used as background. Only gene
sets containing 10 or more genes were considered and
p-values were adjusted using the Benjamini-Hochberg
procedure. The analysis was performed using various
feature importance thresholds scanning across the top
quantile of absolute feature importance values.
Structural alerts
Derivation of structural alerts
Two algorithms for SA derivation were used, with the
DILIrank (−vLessConcern) dataset as input - MoSS and
SARpy. MoSS is a graph-based depth-first search
method used for chemical substructure mining [26] and
we used the KNIME (v3.7.2.) [61] implementation of
MoSS in the current study. It derives potential SAs as
“subgraphs” with only heavy atoms, which are neither
SMILES nor SMARTS. Users might decide to approxi-
mate the subgraphs with SMARTS in order to match
the substructure to molecules (denoted by SMILES).
This program searches for frequent molecular substruc-
tures and discriminative fragments in a set of molecule
graphs. In a graph, a vertex is a representation of an
atom and an edge is a representation of a bond. Each
vertex has attributes related to atom type, charge, and
whether it is a part of an aromatic ring. Edges indicate
the bond type. The search starts from the root of the
graph tree being a single atom and follows recursively
through atoms linked to leaf atoms with subsequent
bonds. Substructures are then created based on each
state of the graph tree and are pruned if the substructure
occurrence in the active class is lower than the defined
minimum focus support (MFS).
In order to find a discriminative fragment, two thresh-
olds should be defined by the user. The first one is the
aforementioned MFS used for pruning and the second
one is minimum complement support (MCS) i.e. the
substructure occurrence in the inactive class. The fol-
lowing KNIME MoSS settings were chosen: 1% MFS
(the minimum fraction of the fragment-contained che-
micals in the DILI positive class - the true positive rate),
0.01% MCS (the maximum fraction of the fragment-
contained drugs in the DILI negative class - the false
positive rate). In addition, only substructures in which
the number of bonds ranged from 2 to 15 were kept.
Pure carbon fragments were ignored and ring mining
was applied.
SARpy is a string-based search method used for chem-
ical substructure mining [27]. Briefly, SAs in the form of
SMARTS strings are generated by recursively breaking
every combination of bonds working directly on the
SMILES strings of the input dataset. Fragments are then
internally validated against all compounds in the dataset,
and then a reduced set of substructure “rules” is ex-
tracted. In this work’s implementation of SARpy (v.1.0)
the fragmentize function parameters minAtoms and
maxAtoms were set to 2 and 15 respectively, and the
‘target’ (i.e. DILI positive or DILI negative) was set to
None. Structural alerts for DILI were extracted using the
extract function with the parameters: 5 minHits, 1
minLR, and 0 minPrecision. These settings are identical
to those used by Yang et al. (2017) [75], except that a
precision threshold was not applied in order to generate
a larger compendium of SAs to analyze.
Evaluation of structural alerts
Structural alerts’ SMARTS were matched to compounds’
SMILES using the RDKit HasSubstructMatch function in
Python (RDKit 2018.09.3.0). Precision (eq. 2) and cover-
age in DILI positive compounds were both used to as-
sess the predictive performance of the SAs. In addition,
significance measured by p-value was also calculated for
each SAs using the SciPy (version 1.3.0) stats module
fisher_exact function with alternative parameter set to
‘greater’.
Precision Pð Þ ¼
TP
TP þ FPð Þ
ð2Þ
As previously mentioned, because MoSS utilizes a
graph-based search approach it may not consider the
slight difference between aromatic and aliphatic atoms,
leading to mismatches when matching its substructures
to SMILES. For example, in MoSS, “N-C” can match
both aminofuran (NC1 = CC=CO1) and aminotetrahy-
drofuran (NC1CCCO1). However, in SMARTS, “C” is
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different from “c”, so RDKit will not match “N-C” with
aminofuran, because the carbons are aromatic. Despite
this, the significance of these SAs is based on the pres-
ence calculated using RDKit.
To investigate a SA’s presence in already approved and
marketed drugs, SAs were matched to compounds in the
DrugBank database [55] (v.5.1.4) using the RDKit (ver-
sion 2018.09.1) [65] HasSubstructMatch function. This
involved firstly standardizing compounds’ SMILES using
the Python package Standardiser of Atkinson et al.
(2016) [64]. As some SMILES could not be standardized,
this step reduced the total number of DrugBank com-
pounds in the analysis from 2411 to 2136.
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Additional file 1: SI. Overview of gene expression data preparation,
DILI model generation, and DILI label prediction performance for models
derived using L1000 gene expression data. Gene expression data for 14
distinct cell line-time-dose combinations was extracted for all compounds
with DILI labels. Replicate measurements for the same compound were
not aggregated resulting in differing numbers of positive and negative
data points for each dataset. Separate RF and SVM classification models
were trained using either the DILIrank or the DILIrank (−vLessConcern)
datasets for each of the 14 distinct cell line-time-dose combinations. Un-
like models generated using descriptors derived from chemical structure,
the RF and SVM models developed did not achieve meaningfully higher
prediction accuracies than y-scrambling models.
Additional file 2: Figure S1. DILI label prediction performance
(balanced accuracy) of RF and SVM models trained using the DILIrank
(−vLessConcern) dataset and Mordred molecular descriptors for 5-fold
LOCO-CV, external test set, and FDA validation set (Methods). The bal-
anced accuracy for 5-fold internal cross-validation, external test set, and
FDA validation set for 10 models trained using different training data sets
(DILIrank (−vLessConcern), DILIrank, DILIrank (+SIDER)) and training data-
set splits is shown via whisker plots. The median model performance of 3
y-scrambled models is shown as triangles for cross-validation and exter-
nal test set. Predictive accuracy is stable between cross-validation and ex-
ternal test set, but a distinct drop in predictive accuracy is observed
when predicting the FDA validation set.
Additional file 3: Figure S2. DILI label prediction performance
(balanced accuracy) of RF and SVM models trained using the DILIrank
(−vLessConcern) dataset and protein target descriptors for 5-fold LOCO-
CV, external test set, and FDA validation set (Methods). The balanced ac-
curacy for 5-fold internal cross-validation, external test set, and FDA valid-
ation set for 10 models trained using different training data sets (DILIrank
(−vLessConcern), DILIrank, DILIrank (+SIDER)) and training dataset splits is
shown via whisker plots. The median model performance of 3 y-
scrambled models is shown as triangles for cross-validation and external
test set. Predictive accuracy is stable between cross-validation and exter-
nal test set, but a distinct drop in predictive accuracy is observed when
predicting the FDA validation set.
Additional file 4: Figure S3. Enriched pathways across different feature
importance cutoffs for RF using the DILIrank (−vLessConcern) dataset.
Enriched pathways are shown across different feature importance cutoffs
which are identified by the percentile of DILI-enriched protein targets
covered. Significant pathways (FDR < 0.05) are colored by -log (FDR),
pathways without any gene present are shown in white and insignificant
ones in grey. Regulation of TP53 through phosphorylation is the pathway
conserved at the highest threshold identifying significant pathways. Other
identified pathways include arachidonic acid metabolism and prostaglan-
din synthesis.
Additional file 5: Figure S4. Enriched pathways across different feature
importance cutoffs for SVM using the DILIrank (−vLessConcern) dataset.
Enriched pathways are shown across different feature importance cutoffs
which are identified by the percentile of DILI-enriched protein targets
covered. Significant pathways (FDR < 0.05) are colored by -log (FDR),
pathways without any gene present are shown in white and insignificant
ones in grey. While some pathways are only significant at high thresh-
olds, such as steroid hormone biosynthesis, others are only found at
lower thresholds, e.g. TLR signaling. Additionally, a set of pathways in-
cluding biotransformation, cytochrome 450 and arachidonic acid metab-
olism are observed across the majority of thresholds.
Additional file 6: Table S1. Performance of models trained using the
DILIrank (−vLessConcern) dataset. Shown is mean ± standard deviation
for 7 metrics (MCC - Matthew’s Correlation Coefficient, PRAUC - Precision-
Recall Area Under Curve, ROCAUC - Receiver-Operator-Characteristic Area
Under Curve) for models trained using ECFP4, Mordred molecular de-
scriptors (MD), and protein target descriptors (PT). Row names correspond
to the descriptor type, algorithm, and the test set - external test set (ET),
FDA validation set (FDA). The best external test set and FDA validation
set performance per metric are shown in bold. For the FDA validation
set, PRAUC and ROCAUC were not available as only the confusion matri-
ces of the predictions were provided by CAMDA. The model trained
using SVM and ECFP4 descriptors achieved the best performance over
the FDA validation set.
Additional file 7: TableS2. Proteins with high feature importance in RF
and SVM, and links to DILI. The 19 proteins with the highest feature
importance in RF or SVM models are shown. The feature importance is
shown in bold if the protein ranked among the top 19 in the respective
model. Many proteins identified possess known functions in liver drug
metabolism and cell stress. Those proteins with plausible involvement in
DILI are indicated in italics.
Additional file 8: TableS3. Pathways with high feature importance in
RF and SVM, and links to DILI. The overrepresented gene sets for 19
proteins with the highest feature importance in RF or SVM models are
shown. Many pathways identified possess known functions in liver drug
metabolism and cell stress.
Additional file 9: TableS4. Top significant structural alerts (p-value
≤0.05). The following quality metrics are shown: precision, coverage in
DILI positive compounds (%), and number of Drugbank [44] approved
compounds with the substructure are shown. *MoSS substructure
notation is in the form of subgraphs with only heavy atoms, which are
neither SMILES nor SMARTS.
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